The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Open accessAbstract
PURPOSE: There is limited evidence on the clinical utility of monitoring measurable residual disease (MRD) in patients with acute myeloid leukemia treated with lower-intensity therapy. Herein, we explored the outcomes of patients treated with venetoclax and azacitidine who achieved composite complete remission (CRc; complete remission + complete remission with incomplete hematologic recovery) and MRD < 10–3 in the VIALE-A trial. METHODS: The patients included in this report were treated with venetoclax and azacitidine. Bone marrow aspirate samples for multiparametric flow cytometry assessments were collected for central analysis at baseline, end of cycle 1, and every three cycles thereafter. MRD-negative response was defined as < 1 residual blast per 1,000 leukocytes (< 10–3 or 0.1%) with an estimated analytic sensitivity of 0.0037%-0.0027%. CRc, duration of remission (DoR), event-free survival (EFS), and overall survival (OS) were assessed. A multivariate Cox regression analysis identified prognostic factors associated with OS. RESULTS: One hundred sixty-four of one hundred ninety (86%) patients with CRc were evaluable for MRD. MRD < 10–3 was achieved by 67 of 164 (41%), and 97 of 164 (59%) had MRD ≥ 10–3. The median DoR, EFS, and OS were not reached in patients with CRc and MRD < 10–3, and the 12-month estimates for DoR, EFS, and OS in this group were 81.2%, 83.2%, and 94.0%. Among patients with CRc and MRD ≥ 10–3, the median DoR, EFS, and OS were 9.7, 10.6, and 18.7 months. Multivariate analysis showed that CRc with MRD < 10–3 was a strong predictor of OS (adjusted hazard ratio = 0.285; 95% CI, 0.159 to 0.510; P < .001). CONCLUSION: Patients who achieved CRc and MRD < 10–3 with venetoclax and azacitidine had longer DoR, EFS, and OS, than responding patients with MRD ≥ 10–3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Self-citation
Research works printed but not linked: 16
- National Comprehensive Cancer Network, 2021, NCCN Guidelines for Patients with Acute Myeloid Leukemia, Version 3.2021
- 10.1182/blood-2005-09-3724 · DOI · Paper page
- 10.1002/cncr.21723 · DOI · Paper page
- 10.1053/j.seminoncol.2008.04.009 · DOI
- 10.1007/s00277-015-2364-5 · doi:10.1007/s00277-015-2364-5
- 10.1200/JCO.2012.45.9628 · DOI · Paper page
- 10.1200/JCO.2013.49.1753 · DOI · Paper page
- 10.1038/leu.2017.285 · DOI
- 10.1182/blood-2016-08-733196 · DOI · Paper page
- 10.1182/blood-2017-09-801498 · DOI · Paper page
- Thermo Fisher Scientific, Real-Time PCR
- 10.3390/jcm9061714 · doi:10.3390/jcm9061714
- 10.1200/JCO.2003.04.036 · DOI · Paper page
- US Department of Health and Human Services: National Cancer Institute, 2018, Common Terminology Criteria for Adverse Events (CTCAE) v4.03
- 10.1182/bloodadvances.2020003717 · DOI
- 10.1056/NEJMoa1716863 · DOI · Paper page
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Self-citationAcute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management
Shimony, S., Stahl, M., & Stone, R. M. (2023) · American Journal of Hematology · doi:10.1002/ajh.26822 · Cited by 448
DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00108-3 · Cited by 437
Self-citationThe manipulation of apoptosis for cancer therapy using BH3-mimetic drugs
Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00407-4 · Cited by 346
Pollyea, D. A., Pratz, K. W., Wei, A. H., Pullarkat, V., Jonas, B. A., Recher, C., Babu, S., Schuh, A. C., Dail, M., Sun, Y., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1183 · Cited by 159
Self-citation
Metadata
- Authors
- Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., Yeh, S.-P., Jang, J. H., Ozcan, M., Yamamoto, K., Illes, A., Zhou, Y., Dail, M., Chyla, B., Potluri, J., & Döhner, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-03-10
- Volume
- 40
- Issue
- 8
- Pages
- 855-865
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4200103238
- Cited by
- 179
- References
- 1
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. https://app.cochat.ai/papers/10.1200/jco.21.01546
- The paper
- Pratz, K. W., Jonas, B. A., Pullarkat, V., Recher, C., Schuh, A. C., Thirman, M. J., Garcia, J. S., DiNardo, C. D., Vorobyev, V., Fracchiolla, N. S., Yeh, S.-P., Jang, J. H., Ozcan, M., Yamamoto, K., Illes, A., Zhou, Y., Dail, M., Chyla, B., Potluri, J., & Döhner, H. (2022). Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.01546
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.